A newly revealed molecular tug-of-war may have implications for better understanding how a multitude of diseases and ...
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 DiabetesSAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” ...
BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback